Cervical Intraepithelial Neoplasia Grade 2/3

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Asieris Pharmaceuticals
1 program
1
Cevira®Phase 31 trial
Active Trials
NCT04484415UnknownEst. Dec 2023
Papivax
PapivaxTaiwan - Taipei
1 program
1
PVX4 Combination ProductPhase 21 trial
Active Trials
NCT07454915Not Yet RecruitingEst. Jun 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Asieris PharmaceuticalsCevira®
PapivaxPVX4 Combination Product

Clinical Trials (2)

NCT04484415Asieris PharmaceuticalsCevira®

Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)

Start: Nov 2020Est. completion: Dec 2023
Phase 3Unknown
NCT07454915PapivaxPVX4 Combination Product

PVX4 for the Treatment of HPV16+ Cervical Dysplasia

Start: Mar 2026Est. completion: Jun 2028
Phase 2Not Yet Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space